Enhanced Oral Bioavailability of Efavirenz by Solid Lipid Nanoparticles: In Vitro Drug Release and Pharmacokinetics Studies

Table 3

Drug and excipients compatibility study by IR.

Components	Functional groups and wave number (cm^−1)
Drug	3318	2940.39	1749.74	1096, 1057, 1074
	(NH str)	(CH str)	(C=O str)	(C–O–C str)
Lipid (GMS)	3336.9	2916.21	1734.18	1098, 1047
	(OH str)	(CH str)	(C=O str)	(C–O–C str)
Surfactant	3433.33, 3453	2923.92, 2936.90	1734.37, 1782	1105.15, 1125.59
	(OH str)	(CH str)	(C=O str)	(C–O–C str)
Drug + lipid	3378.43	2933.59	1736.17
	(OH str)	(CH str)	(C=O str)
Drug + surfactant	3442.78	2923.50, 2926.37	1740.37, 1761.11	1103.68, 1119.59
	(OH str)	(CH str)	(C=O str)	(C–O–C str)
Drug + lipid + surfactant	3410.98, 3439.50	2924.71, 2955.01	1639.54, 1604.68	1040.79, 1053.59
	(OH str)	(CH str)	(C=O str)	(C–O–C str)